A Phase 2 interventional study of cetuximab and bevacizumab in Metastatic Pancreatic Cancer, sponsored by Eli Lilly and Company. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies testing gemcitabine in Pancreatic Neoplasms — 30 open to participants now, 45 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.
Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 106th largest by enrollment of the 353 interventional ones that give a count, is one of 26 that started in 2006, is one of 195 in phase 2, and was the 89th registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →30 of the 370 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Smartwise Sweden AB · Sites in Sweden
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 126 · Phase 2 239 · Phase 3 36 · Phase 4 2
First in 1995; this study’s year is marked. 26 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 353 interventional studies. Of the 268 that completed or were terminated, 80 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 370 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
25 studies in Pancreatic Neoplasms by Eli Lilly and Company: 2 open now, 5 under way, none of them phase 3. Of 18 finished, 11 (61%) have results posted.
Among the 25 studies in Pancreatic Neoplasms by Eli Lilly and Company, this one is the 16th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2006, is one of 7 in phase 2, and was the 5th registered.
Eli Lilly and Company’s Pancreatic Neoplasms studies by the year they started, since 2002.
15 of the studies testing gemcitabine in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT03652428University of Maryland, BaltimorePhase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | 2026-12-31 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 25 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If the patient is on full-dose anticoagulation therapy (eg, warfarin or low molecular weight [LMW] heparin), the following criteria must be met:
If the patient is not on full-dose anticoagulation therapy, the following criteria must be met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
Biological: cetuximab · Biological: bevacizumab · Drug: gemcitabine
Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
Biological: cetuximab · Biological: bevacizumab
I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
Also known as: Erbitux®
10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
Also known as: Avastin®
1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
Also known as: Gemzar®
I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
Also known as: Erbitux®
Progression-free Survival (PFS)
Progression-free survival is the time from randomization until the date of progressive disease (PD) or death from any cause whichever is first reported. Patients who die without a reported prior progression were considered to have progresssed on the day of their death. Patients who did not progress were censored at the day of their last tumor assessment.
Time frame: Time from randomization to disease progression or death from any cause (Range: 0 -10 months)
Overall Survival (OS)
This measure is defined as the time from randomization to the date of death due to any cause. Survival of living patients or those who lost to follow-up were censored on the last date the patients were known to be alive.
Time frame: Survival information was collected continuously every 3 months after completion of therapy and/or follow-up (range: 1-19 months).
The Number of Patients With a Best Overall Response of Either a Complete Response (CR) or Partial Response (PR)
The best overall response is the number of patients with a best overall response of CR or PR, as classifed by the investigator according to the RECIST guidelines. A CR is the disappearance of all target lesions and a PR is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter.
Time frame: Tumor evaluations were performed every 8 weeks while on cetuximab therapy until PD or recurrence. Patients with a PR or CR had a confirmatory tumor assessment no less than 4 weeks after the initial evaluation.
Percentage of Patients With Carbohydrate Antigen 19-9 (CA19-9) Response at End of Cycle 2 in Patients With Elevated Baseline Values (Equal or Greater Than 2 x Upper Limit of Normal).
CA19-9 is a tumor marker for pancreatic cancer and the level usually increases as the disease is progressing. The CA19-9 response was the percentage of patients whose CA19-9 level was declining, stable or increasing \< 10% compared with baseline, divided by the total patients with elevated baseline CA19-9 in that arm.
Time frame: First day of treatment to the end of Cycle 2, Week 1
Time to Progression (TTP)
Time to progression was defined as the time from randomization until the date of objectively confirmed tumor progression was first reported. The censoring rule was consistent with PFS except death. Patients who died from any cause were censored at the time of death or at last tumor assessment date if the death date was missing. For patients lost to follow-up, they were censored at the last tumor assessment date.
Time frame: Time from randomization until the date of objective tumor progression was first reported (range: 11 -38 months)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Reported AEs per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for regulatory Activities dictionary. The National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0 was used to grade all AEs. The collection of AEs began at the time the patient received the first cetuximab dose and continued during the study until 30 days after the last dose of cetuximab. All patients who were enrolled and treated with cetuximab were assessed for safety (mITT population, as treated).
Time frame: An AE was included in the safety analysis if its onset date occurred anytime during cetuximab treatment or up to 30 days after the last dose of cetuximab.
Change From Baseline in Quality of Life (QoL) Assessment Using the Linear Analog Scale Assessment (LASA), Overall QoL at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall QoL question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Overall Mental Well Being, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Mental Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Overall Physical Well Being, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Physical Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Overall Emotional Well Being, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Emotional Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Level of Social Activity, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Social Activity question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Overall Spiritual Well Being, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Spiritual Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up while receiving study drug
Change From Baseline in QoL Assessment Using LASA, Frequency of Pain, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Frequency of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Severity of Pain, Average, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Severity of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up while receiving study drug
Change From Baseline in QoL Assessment Using LASA, Level of Fatigue, Average, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Fatigue question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Level of Support, Friends and Family, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Support, Friends and Family question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Financial Concerns, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Financial Concerns Question question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in QoL Assessment Using LASA, Legal Concerns, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Legal Concerns question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in Assessment of Pain Using the Brief Pain Inventory (BPI) Short Form, Worst Pain, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Worst Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in Assessment of Pain Using BPI Short Form, Least Pain, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Least Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in Assessment of Pain Using BPI Short Form, Average Pain, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Average Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain was 10 and no pain is 0. A negative score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in Assessment of Pain Using BPI Short Form, Pain Right Now, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Pain Right Now question (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Interference question (change from baseline) to Cycle 2 Week 4 is reported. Complete interference is scored as 10 and no interference is scored as 0. A negative score indicates improvement from baseline.
Time frame: Screening, and then every 8 weeks while receiving study drug to 30-day follow-up
Patients were recruited from a population of pancreatic cancer patients treated at investigational centers.
| Milestone | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Started | 30 | 31 |
| Completed | 29 | 29 |
| Not completed | 1 | 2 |
| Withdrew: Hospitalization prior to treatment | 0 | 1 |
| Withdrew: Physician decision prior to treatment | 1 | 0 |
| Withdrew: Withdrawal by subject prior to treatment | 0 | 1 |
Progression-free survival is the time from randomization until the date of progressive disease (PD) or death from any cause whichever is first reported. Patients who die without a reported prior progression were considered to have progresssed on the day of their death. Patients who did not progress were censored at the day of their last tumor assessment.
| months | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Progression-free Survival (PFS) | 3.55 (2.00 to 5.59) | 1.91 (1.81 to 2.76) |
This measure is defined as the time from randomization to the date of death due to any cause. Survival of living patients or those who lost to follow-up were censored on the last date the patients were known to be alive.
| Months | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Overall Survival (OS) | 5.41 (3.84 to 6.74) | 4.17 (2.69 to 8.74) |
The best overall response is the number of patients with a best overall response of CR or PR, as classifed by the investigator according to the RECIST guidelines. A CR is the disappearance of all target lesions and a PR is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter.
| Participants | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| The Number of Patients With a Best Overall Response of Either a Complete Response (CR) or Partial Response (PR) | 4 (3.9 to 31.7) | 0 (0.1 to 17.8) |
CA19-9 is a tumor marker for pancreatic cancer and the level usually increases as the disease is progressing. The CA19-9 response was the percentage of patients whose CA19-9 level was declining, stable or increasing \< 10% compared with baseline, divided by the total patients with elevated baseline CA19-9 in that arm.
| Percentage of participants | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Percentage of Patients With Carbohydrate Antigen 19-9 (CA19-9) Response at End of Cycle 2 in Patients With Elevated Baseline Values (Equal or Greater Than 2 x Upper Limit of Normal). | 8 | 9 |
Time to progression was defined as the time from randomization until the date of objectively confirmed tumor progression was first reported. The censoring rule was consistent with PFS except death. Patients who died from any cause were censored at the time of death or at last tumor assessment date if the death date was missing. For patients lost to follow-up, they were censored at the last tumor assessment date.
| months | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Time to Progression (TTP) | 4.11 (2.17 to 5.95) | 2.07 (1.84 to 4.01) |
Reported AEs per patient were coded according to the corresponding preferred term and system organ class in the Medical Dictionary for regulatory Activities dictionary. The National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0 was used to grade all AEs. The collection of AEs began at the time the patient received the first cetuximab dose and continued during the study until 30 days after the last dose of cetuximab. All patients who were enrolled and treated with cetuximab were assessed for safety (mITT population, as treated).
| Participants | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | 29 | 29 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall QoL question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in Quality of Life (QoL) Assessment Using the Linear Analog Scale Assessment (LASA), Overall QoL at Cycle 2 Week 4 | -0.9 ± 2.9 | -0.9 ± 2.3 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Mental Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Overall Mental Well Being, at Cycle 2 Week 4 | 0.6 ± 2.0 | -0.8 ± 1.4 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Physical Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Overall Physical Well Being, at Cycle 2 Week 4 | -0.6 ± 3.1 | -0.6 ± 1.7 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Emotional Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Overall Emotional Well Being, at Cycle 2 Week 4 | -0.2 ± 2.8 | -1.1 ± 2.1 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Social Activity question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Level of Social Activity, at Cycle 2 Week 4 | -1.1 ± 2.9 | 0.6 ± 2.3 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Overall Spiritual Well Being question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Overall Spiritual Well Being, at Cycle 2 Week 4 | -0.4 ± 1.8 | -0.3 ± 1.1 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Frequency of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Frequency of Pain, at Cycle 2 Week 4 | -1.5 ± 2.9 | -2.3 ± 2.6 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Severity of Pain question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Severity of Pain, Average, at Cycle 2 Week 4 | -0.5 ± 2.8 | -0.9 ± 2.4 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Fatigue question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A positive score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Level of Fatigue, Average, at Cycle 2 Week 4 | 1.5 ± 2.3 | 0.3 ± 2.6 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Level of Support, Friends and Family question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Level of Support, Friends and Family, at Cycle 2 Week 4 | 0.1 ± 1.3 | -0.8 ± 1.5 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Financial Concerns Question question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Financial Concerns, at Cycle 2 Week 4 | -0.1 ± 2.4 | 0.9 ± 3.7 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. The primary analysis of pancreatic cancer symptoms was conducted using the LASA QoL questionnaire and was considered exploratory. The Legal Concerns question change from baseline to Cycle 2 Week 4 is reported. The best overall score is 10 and the worst is 0. A negative score indicates worsening from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in QoL Assessment Using LASA, Legal Concerns, at Cycle 2 Week 4 | 0.4 ± 1.7 | 2.3 ± 3.2 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Worst Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in Assessment of Pain Using the Brief Pain Inventory (BPI) Short Form, Worst Pain, at Cycle 2 Week 4 | -1.2 ± 2.8 | 0.5 ± 2.5 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Least Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in Assessment of Pain Using BPI Short Form, Least Pain, at Cycle 2 Week 4 | -0.4 ± 2.0 | 0.9 ± 2.4 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Average Pain (change from baseline) to Cycle 2 Week 4 is reported. The worst pain was 10 and no pain is 0. A negative score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in Assessment of Pain Using BPI Short Form, Average Pain, at Cycle 2 Week 4 | -0.6 ± 1.8 | -0.2 ± 2.1 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Pain Right Now question (change from baseline) to Cycle 2 Week 4 is reported. The worst pain is 10 and no pain is 0. A negative score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in Assessment of Pain Using BPI Short Form, Pain Right Now, at Cycle 2 Week 4 | -0.9 ± 2.6 | 0.9 ± 2.0 |
Accrual on the trial was stopped earlier than planned due to insufficient efficacy on both arms. Analysis of pain using the BPI was considered exploratory. The Interference question (change from baseline) to Cycle 2 Week 4 is reported. Complete interference is scored as 10 and no interference is scored as 0. A negative score indicates improvement from baseline.
| Scores on a scale | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4 | -0.2 ± 2.3 | 0.8 ± 2.9 |
Collected over Adverse events were collected beginning at the time the patient received the initial cetuximab infusion and continued throughout the study until 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab + Bevacizumab + Gemcitabine | — | 21/29 (72.4%) | 29/29 (100%) |
| Cetuximab + Bevacizumab | — | 16/29 (55.2%) | 29/29 (100%) |
| Event | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Disease progressionGeneral disorders | 5/29 | 9/29 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 6/29 | 2/29 |
| Abdominal PainGastrointestinal disorders | 4/29 | 1/29 |
| VomitingGastrointestinal disorders | 1/29 | 4/29 |
| NauseaGastrointestinal disorders | 2/29 | 3/29 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 1/29 | 2/29 |
| DiarrhoeaGastrointestinal disorders | 0/29 | 2/29 |
| FatigueGeneral disorders | 2/29 | 0/29 |
| Urinary tract infectionInfections and infestations | 2/29 | 1/29 |
| CellulitisInfections and infestations | 2/29 | 0/29 |
| Event | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab |
|---|---|---|
| Acneiform dermatitisRespiratory, thoracic and mediastinal disorders | 22/29 | 21/29 |
| FatigueGeneral disorders | 20/29 | 10/29 |
| NauseaGastrointestinal disorders | 14/29 | 14/29 |
| AnorexiaMetabolism and nutrition disorders | 13/29 | 9/29 |
| VomitingGastrointestinal disorders | 11/29 | 9/29 |
| ConstipationCardiac disorders | 11/29 | 7/29 |
| AnemiaBlood and lymphatic system disorders | 9/29 | 1/29 |
| NeutropeniaBlood and lymphatic system disorders | 9/29 | 0/29 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/29 | 0/29 |
| StomatitisGastrointestinal disorders | 9/29 | 7/29 |
| Age, Categorical(Participants) | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 36 |
| >=65 years | 12 | 13 | 25 |
| Age Continuous(years) | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab | Total |
|---|---|---|---|
| Mean | 62.7 ± 11.6 | 62.2 ± 11.4 | 62.4 ± 11.4 |
| Sex: Female, Male(Participants) | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab | Total |
|---|---|---|---|
| Female | 11 | 15 | 26 |
| Male | 19 | 16 | 35 |
| Region of Enrollment(participants) | Cetuximab + Bevacizumab + Gemcitabine | Cetuximab + Bevacizumab | Total |
|---|---|---|---|
| United States | 30 | 31 | 61 |
The record gives a start of May 2006, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine